NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/17/2026 14:02
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization35 mln
Float6.29 mln
Earnings Date08/17/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
19.50
Transformational upside
Relative Strength
98
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-122
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
CervoMed is a Boston-based biotech company focused on treating brain diseases that worsen with age. Its lead drug, neflamapimod, is a pill that enters the brain and blocks a protein linked to nerve cell damage, with the goal of preserving brain function and slowing disease progression. The company is currently testing neflamapimod in patients with several serious conditions, including dementia with Lewy bodies, a progressive speech disorder, and ALS.
